Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Accumulated Expenses (2018 - 2025)

Bicycle Therapeutics' Other Accumulated Expenses history spans 8 years, with the latest figure at $136000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 54.21% year-over-year to $136000.0; the TTM value through Dec 2025 reached $136000.0, down 54.21%, while the annual FY2025 figure was $136000.0, 54.21% down from the prior year.
  • Other Accumulated Expenses reached $136000.0 in Q4 2025 per BCYC's latest filing, down from $204000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.5 million in Q4 2022 to a low of $64000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $455950.0, with a median of $306000.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 1396.88% in 2022, then plummeted 82.54% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $570000.0 in 2021, then surged by 158.25% to $1.5 million in 2022, then crashed by 82.54% to $257000.0 in 2023, then increased by 15.56% to $297000.0 in 2024, then crashed by 54.21% to $136000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Other Accumulated Expenses are $136000.0 (Q4 2025), $204000.0 (Q3 2025), and $236000.0 (Q2 2025).